OrbiMed's accelerated selling plan creates meaningful overhang on ELVN stock. Expect continued selling pressure as the fund works to exit a large position. Monitor for potential follow-on offerings or block trades. The 94% bull consensus may face headwinds from this insider liquidity event.
Price Chart
Executive Summary
OrbiMed Advisors LLC, through OrbiMed Private Investments VII, LP, filed a Form 144 notice of intent to sell approximately 833,800 shares of Enliven Therapeutics (ELVN) valued at roughly $38.3 million, representing about 1.2% of the outstanding float. This is a material liquidation by a large pre-IPO investor following the 2023 merger that formed the company, coming after a period of strong stock performance and prior insider selling.
Key Facts
- OrbiMed (a major healthcare-focused investment firm) filed to sell 833,800 shares via two brokers: Jefferies (787,024 shares, ~$36.2M) and Morgan Stanley (46,776 shares, ~$2.1M).
- The shares were acquired on 02/23/2023 via a merger (the formation merger of Enliven from the IMARA Inc. shell); the cost basis is undisclosed.
- This is an additional intended sale beyond a prior sale on 06/15/2026 of 272,322 shares (~$12.3M), indicating escalating liquidity demand from the same fund.
- The proposed sale represents approximately 1.2% of ELVN's outstanding shares; the total intended sale of ~$38.3M is significant relative to the $2.7B market cap.
- Recent insider activity already showed 4 sells totaling $789K in the past 30 days; this filing dwarfs those prior sales.
Financial Impact
Intent to sell ~833,800 shares valued at ~$38.3 million, plus a prior June 15 sale of 272,322 shares (~$12.3M), totaling over $50M in planned divestiture by the same fund.
Risk Factors
- Continued overhang as OrbiMed reduces or exits its position entirely
- Negative signal: a sophisticated healthcare investor selling post-merger at these levels
- Potential for follow-on secondary offerings if OrbiMed accelerates the timeline
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0000947871-26-000649 |
| Document: 0000947871-26-000649-index.html | 0000947871-26-000649 |
| Document: 0000947871-26-000649.txt | 0000947871-26-000649 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | Insider Cluster | $41.93 | awaiting T+5 | — | $41.52 (−0.98%) |
Oct 19, 2026 7d ago | 144 | $41.25 | awaiting T+5 | — | $41.52 (+0.65%) |
Oct 16, 2026 10d ago | 3 | $38.70 $41.49 | ▲ +7.21% | ▲ +7.35% | $41.52 (+7.29%) |
Oct 14, 2026 12d ago | 8-K | $39.33 $41.93 | ▲ +6.61% | ▲ +7.63% | $41.52 (+5.57%) |
Sep 21, 2026 5w ago | Insider Cluster | $48.19 $46.51 | ▼ −3.49% | ▼ −2.30% | $41.52 (−13.84%) |
Sep 4, 2026 7w ago | 144 | $59.32 $54.43 | ▼ −8.24% | ▼ −7.03% | $41.52 (−30.01%) |
Aug 19, 2026 9w ago | Insider Cluster | $58.97 $60.50 | ▲ +2.59% | ▲ +1.48% | $41.52 (−29.59%) |
Aug 9, 2026 11w ago | Institutional Cluster | $59.42 $59.54 | ▲ +0.19% | ▲ +0.24% | $41.52 (−30.12%) |
Jul 21, 2026 13w ago | Insider Cluster | $52.85 $52.97 | ▲ +0.23% | ▲ +2.63% | $41.52 (−21.44%) |
Jun 22, 2026 18w ago | 144 | $48.60 $50.85 | ▲ +4.63% | ▲ +3.62% | $41.52 (−14.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers